Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Inderberg EM"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-11 z 11
    Tytuł:
    Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
    Autorzy:
    Ellingsen EB; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway. .; Faculty of Medicine, University of Oslo, Oslo, Norway. .; Ultimovacs ASA, Oslo, Norway. .
    Bounova G; ENPICOM B.V., DA 's-Hertogenbosch, Netherlands.
    Kerzeli I; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
    Anzar I; NEC Oncoimmunity, Oslo, Norway.
    Simnica D; Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany.
    Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Guren T; Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Clancy T; NEC Oncoimmunity, Oslo, Norway.
    Mezheyeuski A; HistoOne AB, Uppsala, Sweden.
    Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.
    Mangsbo SM; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.; Ultimovacs AB, Uppsala, Sweden.
    Binder M; Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany.
    Hovig E; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway.
    Gaudernack G; Ultimovacs ASA, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Journal of translational medicine [J Transl Med] 2022 Sep 11; Vol. 20 (1), pp. 419. Date of Electronic Publication: 2022 Sep 11.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Melanoma*/pathology
    Telomerase*
    Humans ; Ipilimumab/pharmacology ; Ipilimumab/therapeutic use ; Tumor Microenvironment ; Vaccination
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Emerging Biomarkers for Immunotherapy in Glioblastoma.
    Autorzy:
    Mensali N; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.
    Inderberg EM; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Apr 12; Vol. 14 (8). Date of Electronic Publication: 2022 Apr 12.
    Typ publikacji:
    Journal Article; Review
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    T cell receptor therapy against melanoma-Immunotherapy for the future?
    Autorzy:
    Winge-Main AK; Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
    Wälchli S; Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
    Inderberg EM; Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Scandinavian journal of immunology [Scand J Immunol] 2020 Oct; Vol. 92 (4), pp. e12927.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Immunotherapy/*methods
    Melanoma/*immunology
    Melanoma/*therapy
    Receptors, Antigen, T-Cell/*immunology
    Skin Neoplasms/*immunology
    Skin Neoplasms/*therapy
    Animals ; Humans ; Melanoma, Cutaneous Malignant
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
    Autorzy:
    Benard E; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Casey NP; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Inderberg EM; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Wälchli S; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Scandinavian journal of immunology [Scand J Immunol] 2020 Oct; Vol. 92 (4), pp. e12917.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Carcinoma, Ovarian Epithelial/*immunology
    Ovarian Neoplasms/*immunology
    Receptors, Chimeric Antigen/*immunology
    Tumor Microenvironment/*immunology
    Animals ; Antigens, Neoplasm/immunology ; Carcinoma, Ovarian Epithelial/therapy ; Female ; Humans ; Immunotherapy, Adoptive/methods ; Ovarian Neoplasms/therapy ; Receptors, Chimeric Antigen/therapeutic use ; Tumor Escape/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Colorectal cysts as a validating tool for CAR therapy.
    Autorzy:
    Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Lie M; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Baken E; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Lobert VH; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Benard E; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Köksal H; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. .
    Pokaż więcej
    Źródło:
    BMC biotechnology [BMC Biotechnol] 2020 Jun 01; Vol. 20 (1), pp. 30. Date of Electronic Publication: 2020 Jun 01.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Colorectal Neoplasms/*therapy
    Immunotherapy/*methods
    Immunotherapy, Adoptive/*methods
    B-Lymphocytes/metabolism ; Caco-2 Cells ; Cysts ; Heterografts ; Humans ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism ; Receptors, Chimeric Antigen ; T-Lymphocytes/immunology ; Tumor Microenvironment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients.
    Autorzy:
    Andersson Y; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Department of Oncology, Østfold Hospital Trust, Grålum, Norway.
    Inderberg EM; Department of Cellular Therapy, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
    Kvalheim G; Department of Cellular Therapy, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
    Herud TM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
    Engebraaten O; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Flatmark K; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterological Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
    Dueland S; Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Fodstad Ø; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Apr; Vol. 59 (4), pp. 404-409. Date of Electronic Publication: 2019 Dec 26.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article
    MeSH Terms:
    Colorectal Neoplasms/*mortality
    Cyclosporine/*therapeutic use
    Epithelial Cell Adhesion Molecule/*antagonists & inhibitors
    Immunoconjugates/*therapeutic use
    Immunotoxins/*therapeutic use
    Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy ; Epithelial Cell Adhesion Molecule/immunology ; Epithelial Cell Adhesion Molecule/metabolism ; Humans ; Immunosuppressive Agents/therapeutic use ; Neoplasm Metastasis ; Prognosis ; Survival Rate
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Posttransplantation Lymphoproliferative Disease Treated by Retransplantation.
    Autorzy:
    Weum Abrahamsen I; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
    Grønvold BC; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
    Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
    Mensali N; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
    Mattsson J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
    Gedde-Dahl T; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Case reports in immunology [Case Reports Immunol] 2020 Feb 25; Vol. 2020, pp. 9403123. Date of Electronic Publication: 2020 Feb 25 (Print Publication: 2020).
    Typ publikacji:
    Case Reports
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Treating osteosarcoma with CAR T cells.
    Autorzy:
    Köksal H; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Müller E; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Inderberg EM; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Bruland Ø; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
    Wälchli S; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Scandinavian journal of immunology [Scand J Immunol] 2019 Mar; Vol. 89 (3), pp. e12741. Date of Electronic Publication: 2019 Jan 15.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Bone Neoplasms/*therapy
    Immunotherapy, Adoptive/*methods
    Osteosarcoma/*therapy
    Bone Neoplasms/immunology ; Bone Neoplasms/mortality ; Cancer-Associated Fibroblasts/physiology ; Endopeptidases ; Gangliosides/antagonists & inhibitors ; Gelatinases/physiology ; Humans ; Membrane Proteins/physiology ; Osteosarcoma/immunology ; Osteosarcoma/mortality ; Receptor, ErbB-2/analysis ; Receptor, IGF Type 1/physiology ; Receptors, Interleukin-11/antagonists & inhibitors ; Serine Endopeptidases/physiology ; Tumor Microenvironment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Artesunate shows potent anti-tumor activity in B-cell lymphoma.
    Autorzy:
    Våtsveen TK; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway. .; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway. .
    Myhre MR; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway.; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.; Department of Computer Science, University of Oslo, Oslo, Norway.
    Wälchli S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway.; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Lingjærde OC; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.; Department of Computer Science, University of Oslo, Oslo, Norway.
    Bai B; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway.; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
    Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Theodossiou TA; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Holien T; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Hematology, St. Olav's Hospital HF, Trondheim, Norway.
    Sundan A; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Hematology, St. Olav's Hospital HF, Trondheim, Norway.
    Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
    Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway.; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
    Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway.; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
    Oksvold MP; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Ullernschausseen 70, Montebello, 0379, Oslo, Norway.; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2018 Feb 20; Vol. 11 (1), pp. 23. Date of Electronic Publication: 2018 Feb 20.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents/*pharmacology
    Artesunate/*pharmacology
    Lymphoma, B-Cell/*drug therapy
    Animals ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Artesunate/therapeutic use ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Glycolysis/drug effects ; Humans ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/metabolism ; Lymphoma, B-Cell/pathology ; Mice ; Transcriptome/drug effects ; Unfolded Protein Response/drug effects ; Xenograft Model Antitumor Assays
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    CD8+ immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12/interleukin-18 and induce T helper 1 autoantibody.
    Autorzy:
    Noble A; Department of Immunology, Guy's, King's and St Thomas' School of Medicine, King's College London, London, UK. />Leggat JA
    Inderberg EM
    Pokaż więcej
    Źródło:
    Immunology [Immunology] 2003 Aug; Vol. 109 (4), pp. 476-86.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    CD8-Positive T-Lymphocytes/*immunology
    Dendritic Cells/*immunology
    Graft vs Host Reaction/*immunology
    Interleukin-12/*immunology
    Interleukin-18/*immunology
    Th1 Cells/*immunology
    Animals ; Autoantibodies/immunology ; CD4-Positive T-Lymphocytes/immunology ; Enzyme-Linked Immunosorbent Assay/methods ; Immunoglobulin E/immunology ; Immunoglobulin G/immunology ; Immunologic Memory/immunology ; Interferon-gamma/immunology ; Lymphocyte Culture Test, Mixed ; Mice ; Mice, Inbred BALB C ; Th2 Cells/immunology ; Tumor Necrosis Factor-alpha/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-11 z 11

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies